NVCT vs. MRVI, URGN, AUTL, CDXC, CDTX, ABUS, EOLS, UPB, XNCR, and SAGE
Should you be buying Nuvectis Pharma stock or one of its competitors? The main competitors of Nuvectis Pharma include Maravai LifeSciences (MRVI), Urogen Pharma (URGN), Autolus Therapeutics (AUTL), ChromaDex (CDXC), Cidara Therapeutics (CDTX), Arbutus Biopharma (ABUS), Evolus (EOLS), Upstream Bio (UPB), Xencor (XNCR), and Sage Therapeutics (SAGE). These companies are all part of the "pharmaceutical products" industry.
Nuvectis Pharma vs. Its Competitors
Nuvectis Pharma (NASDAQ:NVCT) and Maravai LifeSciences (NASDAQ:MRVI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Nuvectis Pharma currently has a consensus price target of $17.00, indicating a potential upside of 116.56%. Maravai LifeSciences has a consensus price target of $6.64, indicating a potential upside of 155.34%. Given Maravai LifeSciences' higher possible upside, analysts clearly believe Maravai LifeSciences is more favorable than Nuvectis Pharma.
In the previous week, Maravai LifeSciences had 2 more articles in the media than Nuvectis Pharma. MarketBeat recorded 2 mentions for Maravai LifeSciences and 0 mentions for Nuvectis Pharma. Maravai LifeSciences' average media sentiment score of 1.02 beat Nuvectis Pharma's score of 0.00 indicating that Maravai LifeSciences is being referred to more favorably in the news media.
Nuvectis Pharma has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat Nuvectis Pharma's return on equity.
96.8% of Nuvectis Pharma shares are owned by institutional investors. Comparatively, 50.3% of Maravai LifeSciences shares are owned by institutional investors. 30.5% of Nuvectis Pharma shares are owned by insiders. Comparatively, 2.1% of Maravai LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Nuvectis Pharma has higher earnings, but lower revenue than Maravai LifeSciences. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
Nuvectis Pharma has a beta of -0.25, indicating that its stock price is 125% less volatile than the S&P 500. Comparatively, Maravai LifeSciences has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.
Summary
Maravai LifeSciences beats Nuvectis Pharma on 9 of the 15 factors compared between the two stocks.
Get Nuvectis Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVCT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NVCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuvectis Pharma Competitors List
Related Companies and Tools
This page (NASDAQ:NVCT) was last updated on 7/8/2025 by MarketBeat.com Staff
Free NVCT Stock Alerts